Sage Therapeutics: Guggenheim's favorite among 11 biotechs

Inflarx NV

22/02/2019 12:29

** Brokerage Guggenheim says Sage Therapeutics  SAGE.O  is
its top pick after initiating coverage on 11 companies focused
on developing treatments for inflammation and central nervous
system disorders
    ** In light of abating growth in several large-therapeutic
categories, Guggenheim analysts say they expect large-cap
companies to remain acquisitive in the central nervous system
space and advise investors to overweight small-mid-cap names
    ** Brokerage says Sage's depression drugs could be
paradigm-changing for patients and sees "more mileage left" in
co's stock despite a ~50 pct YTD rise; sets "buy" rating
    ** Guggenheim also "buy" rated on AnaptysBio Inc  ANAB.O ,
Argenx SE  ARGX.BR , Global Blood Therapeutics  GBT.O , GW
Pharmaceuticals  GWPH.O , among others
    ** However, brokerage cautious on large-cap companies
Regeneron  REGN.O , Alexion  ALXN.O  and Biogen  BIIB.O  over
growth concerns, competition fears and lack of conviction in
development candidates 
 Company name               Guggenheim's    Price
                            Rating          target 
 AnaptysBio Inc             Buy             $135
 Argenx SE                  Buy             $157
 Global Blood Therapeutics  Buy             $75
 GW Pharmaceuticals         Buy             $178
 Inflarx NV  IFRX.O         Buy             $65
 Ra Pharmaceuticals Inc     Buy             $48
  RARX.O                                    
 Zogenix Inc  ZGNX.O        Buy             $70
 Sage Therapeutics          Buy             $205
 Alexion Pharmaceuticals    Neutral         $135
 Biogen Inc                 Neutral         $325
 Regeneron                  Neutral         $425
 
 (Reporting by Manas Mishra in Bengaluru)
 ((Reuters Messaging:
manas.mishra.thomsonreuters.com@reuters.net))